Drug and pharmaceutical recalls
354 federal recalls in the last 12 months. Federal recalls for prescription drugs, OTC medications, supplements, and pharmaceuticals. Sourced from the FDA and translated into plain English.
Recent recalls
Page 4 of 12- American Health Packaging buprenorphine tablets recalled for label mix-up
American Health Packaging distributed buprenorphine sublingual tablets with incorrect labeling. The affected medication is a prescription opioid used to treat pain and opioid use disorder. A label mix-up could result in dosing errors if patients or healthcare providers rely on incorrect information.
ModerateFDASep 9, 2026American Health Packaging
- Mylan prasugrel tablets recalled for failed dissolution specifications
Mylan Pharmaceuticals is recalling Prasugrel 10mg tablets (Lot #3225272, expiring September 30, 2026) because they failed dissolution testing during 18-month stability studies. This means the tablets may not break down and release the medication as intended in the body. No injuries have been reported.
ModerateFDASep 9, 2026Mylan
- Chiesi Revcovi injection recalled for stability failure
Chiesi USA, Inc. is recalling Revcovi (elapegademase-lvlr) Injection due to out-of-specification stability results in the protein concentration profile. The affected lot was distributed to Missouri and Tennessee. No injuries have been reported.
ModerateFDASep 9, 2026Chiesi
- Sage Products chlorhexidine cloths recalled for cross-contamination
Sage Products is recalling specific lots of 2% Chlorhexidine Gluconate non-sterile cloths due to potential cross-contamination with other products during manufacturing. The affected cloths may not meet safety and quality standards. No injuries have been reported.
ModerateFDASep 9, 2026Sage Products
- Teva trazodone 50 mg recalled for foreign tablets
Teva Pharmaceuticals discovered that some bottles of trazodone 50 mg tablets contain foreign tablets or capsules mixed in with the correct medication. The issue affects one lot (1394026) with an expiration date of February 2028. No injuries have been reported.
ModerateFDASep 9, 2026Teva
- Trokendi XR topiramate capsules recalled for failed dissolution
Supernus Pharmaceuticals is recalling one lot of Trokendi XR (topiramate) 50 mg extended-release capsules because the medication did not dissolve as designed. When a medication fails to dissolve properly, the body may not absorb the full dose, potentially reducing its effectiveness.
ModerateFDASep 9, 2026Supernus
- Mylan Mycophenolate Mofetil injection recalled for dissolution failure
Mylan Pharmaceuticals is recalling specific lots of Mycophenolate Mofetil for injection (500 mg/vial) because the medication failed to meet dissolution specifications—meaning the drug may not dissolve properly in the body. This could affect how well the medicine works. The recall affects two lots distributed nationwide.
ModerateFDASep 9, 2026Mylan
- Broadway Joe's CBD pain cream recalled for possible contamination
The FDA recall covers two Broadway Joe's pain creams containing CBD and hempseed oil, sold in 2 oz and 4 oz jars. The recall was made because of possible contamination of a raw material, found through manufacturing quality issues. The products were distributed in Colorado, and no injuries have been reported.
ModerateFDASep 9, 2026Lexia2 products
- Allies THE ONE SPF 50 gel recalled for reduced SPF
Allies is recalling four sizes of THE ONE SPF 50 Invisible Sunscreen Gel, sold as 3 mL sachets, 20 mL, 50 mL and 90 mL tubes. Testing found the product may not reliably provide the SPF 50 protection stated on the label. No injuries have been reported.
ModerateFDASep 9, 2026Allies4 products
- Bionpharma doxylamine-pyridoxine tablets recalled for foreign tablets
Bionpharma Inc. is recalling Doxylamine Succinate and Pyridoxine HCl Delayed-Release tablets (10 mg/10 mg, 100-count bottles) because some bottles contain unidentified foreign tablets or capsules mixed in with the correct medication. The affected lot is DMA25006 with an expiration date of 11/30/2028. This issue was discovered during quality control.
ModerateFDASep 9, 2026Bionpharma
- Baxter IV drug bags recalled for manufacturing quality issues
Baxter is recalling 17 intravenous (IV) drug products for manufacturing quality problems, called CGMP deviations, which are lapses in the required production standards. The products include vancomycin, daptomycin, clindamycin, famotidine, dexmedetomidine, vasopressin, pantoprazole, insulin, nicardipine, and amiodarone, plus the brand names Myxredlin, CARDENE IV, and Nexterone. They were distributed nationwide, in Puerto Rico, and in Chile, and no injuries have been reported.
ModerateFDASep 9, 2026Baxter17 products
- Golden State prasugrel tablets recalled for failed dissolution
Golden State Medical Supply Inc. is recalling Prasugrel HCI 10mg tablets (lot GS062298, expiration 09/30/2026) because they failed to meet dissolution specifications during quality testing. Dissolution is how quickly a tablet breaks down in the body to release its active ingredient. Tablets that dissolve too slowly or incompletely may not work as intended.
ModerateFDASep 9, 2026Golden State Medical Supply2 products
BMC Luna G3 APAP devices recalled for firmware defectBMC Medical Co., Ltd. recalled 20,160 Luna G3 APAP sleep apnea devices (Model LG3600) due to a firmware defect in version G3-2.00.76. Under certain high-pressure, high-breathing-rate conditions, affected devices can display an error message and shut down automatically, stopping therapy delivery. Most devices were corrected with a firmware upgrade, but up to 196 units may still contain the defective version.
SeriousFDASep 7, 2026BMC Medical
- B. Braun Lactated Ringer's injection recalled for particulate matter
B. Braun Medical has recalled Lactated Ringer's Injection USP in 1000 mL EXCEL containers due to the presence of particulate matter. The affected lot is J4H077 with an expiration date of November 30, 2026. About 23,688 bags were distributed nationwide.
SeriousFDASep 2, 2026B. Braun
- Hikma ramipril capsules recalled for failed impurity specification
Hikma Pharmaceuticals is recalling specific lots of Ramipril Capsules 10 mg because testing found higher-than-allowed levels of dicyclohexylurea, a process impurity. The affected lots are AC5470A and AC5470B, both expiring July 2027. No injuries have been reported.
ModerateFDASep 2, 2026Hikma Pharmaceuticals
- Tyenne tocilizumab injection recalled for glass particles
Fresenius Kabi USA discovered that Tyenne (tocilizumab-aazg) Injection vials may contain glass particles. The contamination was found during an internal investigation. The affected lot is 16UI07, which expires August 31, 2028.
SeriousFDASep 2, 2026Fresenius Kabi
- Paxil CR tablets recalled for failed dissolution specifications
Apotex Corp. is recalling one lot of Paxil CR (paroxetine) 37.5mg extended-release tablets because the medication failed to meet dissolution specifications during 24-month stability testing. This means the tablets may not release the drug into the body as intended. The affected lot (TY9494, expiration 05/31/2027) was distributed nationwide.
ModerateFDASep 2, 2026Apotex
- Mallinckrodt Acthar Gel recalled for glass particulate contamination
Mallinckrodt has recalled specific lots of Acthar Gel (repository corticotropin injection) due to the presence of glass and stopper pieces in the vials. This contamination could pose a risk if the affected medication is used. The recall affects 12,367 vials with lot numbers 1564-107 and 1564-107H, both expiring January 31, 2027.
ModerateFDASep 2, 2026Mallinckrodt
- Zicam cold remedy nasal swabs recalled for microbiological test results
FDA inspection found that Zicam Cold Remedy Medicated Nasal Swabs failed microbiological testing, meaning they may contain harmful microbes. The affected products were manufactured under conditions that did not meet federal safety standards. Specific lot numbers with expiration dates through August 2028 are involved.
ModerateFDASep 2, 2026Arm & Hammer
- Lupin clobetasol cream recalled for failed content uniformity
Lupin Pharmaceuticals is recalling specific lots of Clobetasol Propionate Cream USP 0.05% because the active ingredient is not uniformly distributed throughout the product. This means some parts of the cream may contain too much or too little medication, which could affect how well it works.
ModerateFDASep 2, 2026Lupin
- Accord Healthcare levothyroxine tablets recalled for subpotency
Accord Healthcare is recalling specific lots of levothyroxine sodium tablets (25 mcg) because they contain less active ingredient than labeled. Patients taking these tablets may not receive the full dose needed to manage their thyroid condition. The affected lots were distributed nationwide.
ModerateFDASep 2, 2026Accord Healthcare12 products
B. Braun saline injection recalled for particulate contaminationB. Braun Medical Inc. is recalling three lots of 0.9% Sodium Chloride Injection (saline solution) used in hospitals and healthcare settings. The recalled product contains particles of zinc oxide that should not be present. Intravenous fluids contaminated with particulate matter can cause serious complications including blood clots and organ damage. No injuries have been reported so far.
SeriousFDAAug 27, 2026B. BraunUpdated Sep 3
- Lipofit Extreme 2.0 recalled for undeclared fluoxetine and DNP
Lipofit Extreme Fat Burner 2.0 (Lot 25M12F, expiration 09/2027) contains undeclared fluoxetine, a prescription antidepressant, in the daytime tablets and undeclared 2,4-dinitrophenol (DNP), a toxic pesticide, in the nighttime tablets. Neither ingredient is approved for use in dietary supplements, and DNP is not approved by the FDA for any use in humans.
SeriousFDAAug 27, 2026Lipofit
Baxter sodium citrate solution recalled for fiberglass contaminationBaxter is recalling one lot of Anticoagulant Sodium Citrate Solution used with apheresis devices due to potential fiberglass particles in the solution. The affected product was distributed to one customer in the United States between July 2 and July 11, 2026. No adverse events have been reported to date.
ModerateFDAAug 26, 2026Baxter
- American Regent injectables recalled for glass and hair contamination
American Regent is recalling 12 injectable and oral solution products, including nitroglycerin, cyanocobalamin (vitamin B12), aminocaproic acid, atropine, acetylcysteine, selenious acid, papaverine, niCARdipine, and the trace element products Multrys and Tralement. Some vials may contain particulate matter identified as hair, glass, and/or paraformaldehyde. No injuries have been reported.
ModerateFDAAug 26, 2026American Regent12 products
- Fresenius Kabi morphine syringes recalled for Dilaudid label mixup
Some Fresenius Kabi morphine sulfate prefilled syringes are labeled as morphine 2 mg/mL but actually contain Dilaudid (hydromorphone) 0.5 mg/0.5 mL. This labeling error could lead to patients receiving the wrong medication and dose. The affected lot is 6402820 with an expiration date of 12/2028.
SeriousFDAAug 26, 2026Fresenius Kabi
- Mylan acamprosate calcium tablets recalled for failed dissolution
Mylan Pharmaceuticals is recalling one lot of Acamprosate Calcium 333 mg delayed-release tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication as intended in the body. This could result in ineffective treatment. No injuries have been reported.
ModerateFDAAug 26, 2026Mylan
- Golden State Medical Supply carbamazepine recalled for black specks
Golden State Medical Supply is recalling Carbamazepine Tablets, USP 200mg due to black specks found in some tablets. This is a manufacturing quality issue. The affected lots were distributed nationwide.
ModerateFDAAug 26, 2026Golden State Medical Supply
- Sun Pharmaceutical Carbamazepine recalled for tablet defect
Sun Pharmaceutical's Carbamazepine 200mg tablets (Lot #AD94033, expiring 5/31/2028) contain black spots caused by burnt ingredients during manufacturing. The tablets do not meet quality standards, though no injuries have been reported.
ModerateFDAAug 26, 2026Sun Pharmaceutical
- Regeneron Libtayo injection recalled for sterility concerns
Regeneron is recalling one lot of Libtayo (cemiplimab-rwlc), an intravenous cancer treatment, because the manufacturer cannot guarantee the vials are sterile. This affects lot 8494000002, which expires July 31, 2028. About 21,353 vials are involved in the recall nationwide.
ModerateFDAAug 26, 2026Regeneron